PSN-375,963
PSN-375,963 is a selective ligand for the suggested novel cannabinoid receptor GPR119.[1]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| Chemical and physical data | |
| Formula | C17H23N3O |
| Molar mass | 285.391 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
See also
References
- Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006). "Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents". Cell Metab. 3 (3): 167–175. doi:10.1016/j.cmet.2006.02.004. PMID 16517404.
| Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.